| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.024 | 0.4 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |